Selective Partnerships

BaroFold currently has granted research licenses to companies such as Genentech, Pfizer, Eli Lily and others. Future partnerships will be focused on proprietary proteins or early-production-stage biologics that are challenging to produce by conventional means. BaroFold is seeking to in-license select proprietary biologics whose clinical development will be enabled by PreEMT™.  BaroFold’s IP may enable life-cycle extensions of existing biological drugs by creating proprietary follow-on branded protein therapeutics.  Preferred licensing deals will include later stage or marketed products.